文献速递呼吸道感染间质性肺疾病

吡非尼酮与舒非尼酮在小鼠结核模型中对肺损伤的保护作用

[Protective effect of anti-idiopathic pulmonary fibrosis drug Pirfenidone and Sufenidone (SC1011) on pulmonary injury induced by tuberculosis in a mouse tuberculosis model].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2023-01-01

该研究在C57BL/6小鼠结核模型中评估吡非尼酮(PFD)和舒非尼酮(SC1011)联用HRZ对肺损伤的保护作用。结果显示PFD/SC1011联用HRZ可减轻肺损伤和继发性纤维化,SC1011+HRZ可能降低远期复发率,尤其脾脏复发。

要点

  • PFD或SC1011联用HRZ可降低结核小鼠肺组织羟脯氨酸含量和纤维化面积。
  • SC1011+HRZ组4周血清TNF-α和IFN-γ水平低于HRZ组。
  • SC1011+HRZ组停药12周脾脏复发1/7低于HRZ组5/7,但差异无统计学意义。

核心结论

  • 在C57BL/6小鼠结核模型中,PFD/SC1011与HRZ联用可减轻肺损伤和降低肺结核继发性纤维化。
  • SC1011与HRZ联用对MTB近期治疗效果不显著,但远期可能降低复发率,尤其脾脏复发率。

研究设计与样本

  • 建立C57BL/6小鼠结核病模型,1×10^7 CFU/ml H37Rv菌悬液气溶胶感染75只小鼠。
  • 随机分为未处理组(n=9)、HRZ组(n=22)、PFD+HRZ组(n=22)和SC1011+HRZ组(n=22),感染6周后开始治疗。

主要发现

  • 8周肺组织HYP含量:PFD+HRZ组(630±58)μg/mg、SC1011+HRZ组(635±17)μg/mg、HRZ组(840±70)μg/mg(P<0.05)。
  • 8周Masson染色阳性面积比例:PFD+HRZ组16.65%±1.82%、SC1011+HRZ组10.01%±2.16%、HRZ组21.36%±3.21%(F=27.11,P<0.001)。
  • 8周HE染色肺损伤评分:PFD+HRZ组(5.00±0.50)分、SC1011+HRZ组(5.00±0.47)分、HRZ组(6.89±0.99)分(F=19.81,P<0.001)。
  • 4周ELISA:SC1011+HRZ组血清TNF-α、IFN-γ水平均低于HRZ组(均P<0.05)。
  • 4周肺组织活菌数:PFD+HRZ组(1.82±0.10)、SC1011+HRZ组(1.91±0.05)、HRZ组(1.79±0.17)均低于未处理组(5.27±0.07)lg(CFU+1)/ml,均P<0.05。

关键数值与推荐

  • 停药12周肺部感染复发:SC1011+HRZ组3/7低于HRZ组5/7(P>0.05);PFD+HRZ组6/7高于HRZ组5/7(P>0.05)。
  • 停药12周脾脏感染复发:SC1011+HRZ组1/7低于HRZ组5/7(P>0.05)。
  • 各治疗组给药8周均达到小鼠脾脏无菌化。

临床怎么用

  • 提示PFD/SC1011联用HRZ可能作为减轻结核肺损伤和纤维化的辅助策略。
  • SC1011+HRZ可能有助于降低远期复发,尤其脾脏复发,但需进一步临床验证。

局限性

  • 研究为小鼠模型,结果不能直接外推至人类结核病患者。
  • 复发率比较的P值均>0.05,差异无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the protective effect of anti-idiopathic pulmonary fibrosis (IPF) marketed drug Pirfenidone and its clinical drug Sufenidone (SC1011) against lung injury in a mouse tuberculosis model. Methods: C57BL/6 mouse model of tuberculosis was established. A total of 75 C57BL/6 mice were infected with 1×107 CFU/ml H37Rv suspension by aerosol and randomly divided into untreated (n=9) group, isoniazid+rifampicin+pyrazinamide (HRZ) group (n=22), PFD+HRZ group (n=22), and SC1011+HRZ group (n=22). C57BL/6 mice were infected with H37Rv by aerosol for 6 weeks and then treated. Seven mice in each treatment group were weighed, sacrificed, dissected and observed for lung and spleen lesions at 4 and 8 weeks of treatment. HE staining and Masson staining were used to assess degree of lung injury and fibrosis, respectively. ELISA was used to assess the IFN-γ/TNF-α content in the serum of mice in each treatment group after 4 weeks of treatment. Hydroxyproline (HYP) content in lung tissue was measured by alkaline hydrolysis; meanwhile, CFU counts were used to assess the bacterial load in the lung and spleen of mice in each treatment group and the recurrence of spleen and lung tissue after 12 weeks of drug withdrawal. Results: At 8 weeks, the HYP content in the lung tissue was (630±58), (635±17), and (840±70) μg/mg in the PFD+HRZ, SC1011+HRZ, and HRZ treatment group, respectively (P<0.05).At 8 weeks, the proportion of Masson staining blue-stained area, that was, positive area, in lung tissue was 16.65%±1.82%, 10.01%±2.16%, and 21.36%±3.21%, respectively (F=27.11, P<0.001).The lung injury scores by HE staining at 8 weeks were (5.00±0.50), (5.00±0.47), and (6.89±0.99) points, respectively (F=19.81, P<0.001).The results of 4-week ELISA showed that the levels of TNF-α and IFN-γ in the serum of the SC1011+HRZ-treated group were lower than those of the HRZ-treated group (all P<0.05).The degree of lung injury and fibrosis in PFD+HRZ and SC1011+HRZ treatment groups were lower than those in HRZ treatment group (all P<0.001). The number of viable bacteria in the lung tissue of mice treated with PFD+HRZ, SC1011+HRZ, and HRZ for 4 weeks was lower than that of mice untreated [(1.82±0.10), (1.91±0.05), (1.79±0.17) vs. (5.27±0.07) lg(CFU+1)/ml, all P<0.05)]. And the aseptic transformation of the spleen of mice was achieved in each treatment group at 8 weeks of administration. After 12 weeks of drug withdrawal, the recurrence of lung infection in the SC1011+HRZ treatment group was 3/7 lower than 5/7 in the HRZ treatment group (P>0.05); the recurrence of spleen infection in the SC1011+HRZ treatment group was 1/7 lower than 5/7 in the HRZ treatment group (P>0.05).Pulmonary infection recurred more frequently in PFD+HRZ 6/7 versus HRZ 5/7 (P>0.05). Conclusions: PFD/SC1011, when combined with HRZ, reduced lung injury and reduced secondary fibrosis in pulmonary tuberculosis in C57BL/6 mice. SC1011 combined with HRZ has no significant short-term therapeutic effect on MTB, but may reduce its recurrence rate in long-term treatment, especially in reducing the recurrence rate of mouse spleen. 目的: 在小鼠结核病模型中评价抗特发性肺纤维化上市药物吡非尼酮(Pirfenidone,PFD)和临床药物舒非尼酮(SC1011)对肺损伤的保护作用。 方法: 建立C57BL/6小鼠结核病模型。1×107 CFU/ml H37Rv菌悬液通过气溶胶感染75只C57BL/6小鼠,随机数字表法分为未处理组(n=9)、异烟肼H+利福平R+吡嗪酰胺Z(HRZ)治疗组(n=22)、PFD+HRZ治疗组(n=22)和SC1011+HRZ治疗组(n=22)。感染6周后开始给药治疗,分别于给药4、8周取各治疗组7只小鼠进行称重、处死、解剖、观察肺脏和脾脏病变;HE染色、Masson染色,评估肺损伤和肺纤维化程度;ELISA法评估治疗4周各治疗组小鼠血清中IFN-γ/TNF-α含量。碱水解法测定肺组织中羟脯氨酸(hydroxyproline,HYP)含量;同时通过CFU计数,评估各治疗组小鼠肺脾内的载菌量及停药12周后脾、肺组织的复发情况。 结果: 8周PFD+HRZ治疗组、SC1011+HRZ治疗组、HRZ治疗组肺组织HYP含量分别为(630±58)、(635±17)、(840±70)μg/mg(P<0.05);8周肺组织Masson染色蓝染区域面积即阳性面积比例分别为16.65%±1.82%、10.01%±2.16%、21.36%±3.21%(F=27.11,P<0.001);8周HE染色肺损伤评分分别为(5.00±0.50)、(5.00±0.47)、(6.89±0.99)分(F=19.81,P<0.001)。4周ELISA实验结果显示SC1011+HRZ治疗组血清中TNF-α、IFN-γ水平均低于HRZ治疗组(均P<0.05)。PFD+HRZ、SC1011+HRZ治疗组肺损伤程度以及肺纤维化程度均低于HRZ治疗组(均P<0.001)。PFD+HRZ、SC1011+HRZ、HRZ三个治疗组治疗4周小鼠肺组织中活菌数量均低于未处理组[(1.82±0.10)、(1.91±0.05)、(1.79±0.17)比(5.27±0.07)lg(CFU+1)/ml,均P<0.05],并且各治疗组均在给药8周达到小鼠脾脏无菌化。停药12周后,SC1011+HRZ治疗组的肺部感染复发情况低于HRZ治疗组(3/7比5/7,P>0.05);SC1011+HRZ治疗组的脾脏感染复发情况低于HRZ治疗组(1/7比5/7,P>0.05)。PFD+HRZ治疗组的肺部感染的复发情况高于HRZ治疗组(6/7比5/7,P>0.05)。 结论: 在C57BL/6小鼠结核病模型中,PFD/SC1011与HRZ联用可以减轻肺损伤和降低肺结核继发性纤维化。SC1011与HRZ联用时对MTB的近期治疗效果不显著,但在远期治疗上可能降低其复发率,尤其在降低小鼠脾脏的复发率上作用明显。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qi XT, Zheng LY, Fu L, et al. [Protective effect of anti-idiopathic pulmonary fibrosis drug Pirfenidone and Sufenidone (SC1011) on pulmonary injury induced by tuberculosis in a mouse tuberculosis model]. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36990703. doi:10.3760/cma.j.cn112147-20220914-00758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。